Aurobindo Pharma’s Q2 net up 4.6% at ₹640 cr

Our Bureau Hyderabad | Updated on November 13, 2019

The scrip gains 2.5 per cent after opening of trade

Aurobindo Pharma Ltd’s net profit increased 4.6 per cent at ₹640 crore in the second quarter ended September 30, 2019 compared to ₹611 crore in the corresponding quarter of the previous year.

The total revenue of the Hyderabad based company increased 17.9 per cent at ₹5,600 crore against ₹4,751 crore.

“We had a quarter of healthy performance where we continued to grow in US and Europe, which are our focused geographies. Our R&D initiatives have been progressing well across the products basket and we have started clinical trials for our first biosimilar product in Q3FY20,’’ N. Govindarajan, Managing Director, Aurobindo Pharma said in a release.

The company was in the process of resolving all pending regulatory issues, he added.

Revenue from US formulations increased 27.3 per cent at ₹2,835.5 crore (₹2,227 crore). Europe formulations revenue stood at ₹1,401 cr, which is an increase of 21.2 per cent against last year. Growth Markets posted a growth of 3.8 per cent.

Research & Development (R&D) spend was at Rs 223 cr, amounting to 4 pc of revenues Basic and diluted EPS is Rs 10.92 per share.

Aurobindo’s board approved an Interim Dividend at 125 per cent for ₹1.25 per equity share of Re. 1/- each on the equity share capital of the company for the Financial Year 2019-20.

Aurobindo’s scrip gained 2.58 per cent after opening of trade on the Bombay Stock Exchange on Wednesday.

Published on November 13, 2019

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

This article is closed for comments.
Please Email the Editor

You May Also Like